• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艾滋病毒疫苗试验入组障碍:艾滋病毒疫苗准备研究综述。

Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.

机构信息

University of British Columbia, Vancouver, BC, Canada.

出版信息

Vaccine. 2011 Aug 11;29(35):5850-9. doi: 10.1016/j.vaccine.2011.06.055. Epub 2011 Jul 6.

DOI:10.1016/j.vaccine.2011.06.055
PMID:21740947
Abstract

Barriers to participation in an HIV vaccine trial have been examined in many HIV vaccine preparedness studies (VPS). These barriers can be understood in terms of the locus of the barrier (personal vs. social) and the nature of the barrier (risk vs. cost). Another type of barrier is perceived misconceptions. In this systematic review, we categorize barriers, and compare these barriers between the Organization for Economic Co-operation and Development (OECD) countries and the non-OECD countries. In the OECD countries, we retrieved 25 studies reporting personal risks (PR), 9 studies reporting social risks (SR), 10 studies reporting personal costs (PC), and 16 studies reporting misconceptions. In the non-OECD countries, we retrieved 27 studies reporting PR, 19 studies reporting SR, 18 studies reporting PC, 1 study reporting social costs (SC), and 13 studies reporting misconceptions. Important PR were "adverse effects" and "vaccine-induced seropositivity", "distrust of institutions", and "temptation to have unsafe sex" in men who have sex with men (MSM). "Discrimination" was a common SR. "Time commitment" was an important PC, and "family commitments" were a SC in one non-OECD country. "HIV infection from the vaccine" was a common misconception. Both the OECD and the non-OECD countries have similar barriers, and people's decisions to participate in a clinical trial involve multiple barriers. However, these barriers apply to hypothetical HIV vaccine trials, and barriers for actual vaccine trials need further assessment.

摘要

参与 HIV 疫苗试验的障碍已在许多 HIV 疫苗预备研究 (VPS) 中进行了研究。这些障碍可以根据障碍的位置(个人与社会)和障碍的性质(风险与成本)来理解。另一种类型的障碍是感知上的误解。在这项系统评价中,我们对障碍进行了分类,并比较了经合组织 (OECD) 国家和非经合组织国家之间的这些障碍。在 OECD 国家,我们检索到 25 项报告个人风险 (PR) 的研究、9 项报告社会风险 (SR) 的研究、10 项报告个人成本 (PC) 的研究和 16 项报告误解的研究。在非经合组织国家,我们检索到 27 项报告 PR 的研究、19 项报告 SR 的研究、18 项报告 PC 的研究、1 项报告 SC 的研究和 13 项报告误解的研究。男男性行为者 (MSM) 中的重要 PR 包括“不良影响”和“疫苗引起的血清阳性”、“对机构的不信任”和“有不安全性行为的诱惑”。“歧视”是一种常见的 SR。“时间承诺”是一个重要的 PC,而在一个非经合组织国家,“家庭承诺”是一个 SC。“从疫苗感染 HIV”是一个常见的误解。OECD 和非经合组织国家都有类似的障碍,人们参与临床试验的决定涉及多个障碍。然而,这些障碍适用于假设的 HIV 疫苗试验,实际疫苗试验的障碍需要进一步评估。

相似文献

1
Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.艾滋病毒疫苗试验入组障碍:艾滋病毒疫苗准备研究综述。
Vaccine. 2011 Aug 11;29(35):5850-9. doi: 10.1016/j.vaccine.2011.06.055. Epub 2011 Jul 6.
2
Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.参与HIV疫苗试验的动机:HIV疫苗准备研究综述
AIDS Care. 2011 Nov;23(11):1430-47. doi: 10.1080/09540121.2011.555750. Epub 2011 Jul 4.
3
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.降低男男性行为者中艾滋病毒性传播风险的行为干预措施。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
4
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.肺炎球菌结合疫苗的免疫原性和血清效力:系统评价和网络荟萃分析。
Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079.
5
Population-based interventions for reducing sexually transmitted infections, including HIV infection.基于人群的减少性传播感染(包括艾滋病毒感染)的干预措施。
Cochrane Database Syst Rev. 2004(2):CD001220. doi: 10.1002/14651858.CD001220.pub2.
6
Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection.基于人群的生物医学性传播感染控制干预措施以减少艾滋病毒感染。
Cochrane Database Syst Rev. 2011 Mar 16(3):CD001220. doi: 10.1002/14651858.CD001220.pub3.
7
HIV vaccine preparedness studies in the non-organization for economic co-operation and development (non-OECD) countries.非经济合作与发展组织(非经合组织)国家的HIV疫苗准备研究。
AIDS Care. 2009 Mar;21(3):335-48. doi: 10.1080/09540120802183545.
8
Antidepressants for depression in adults with HIV infection.用于感染HIV的成年抑郁症患者的抗抑郁药。
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD008525. doi: 10.1002/14651858.CD008525.pub3.
9
Population-based interventions for reducing sexually transmitted infections, including HIV infection.基于人群的减少性传播感染(包括艾滋病毒感染)的干预措施。
Cochrane Database Syst Rev. 2001(2):CD001220. doi: 10.1002/14651858.CD001220.
10
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.

引用本文的文献

1
Barriers and facilitators of participation in syphilis vaccine trials: a qualitative analysis to inform trial design and community engagement in the United States.参与梅毒疫苗试验的障碍与促进因素:一项旨在为美国试验设计和社区参与提供信息的定性分析
Sex Reprod Health Matters. 2024 Dec;32(1):2473199. doi: 10.1080/26410397.2025.2473199. Epub 2025 May 2.
2
Determinants of an HIV Preventive Vaccine among a Highly Vulnerable Population: African American Men Who Have Sex with Men.高危人群中一种HIV预防性疫苗的决定因素:与男性发生性关系的非裔美国男性
Vaccines (Basel). 2024 Mar 18;12(3):323. doi: 10.3390/vaccines12030323.
3
Preparing for future European efficacy trials of interventions to prevent HIV and other sexually transmitted infections: Lessons on willingness to participate and barriers to participation from ten German clinics serving behaviorally vulnerable men who have sex with men.
为未来欧洲预防艾滋病毒和其他性传播感染干预措施的疗效试验做准备:来自为男男性行为易感染人群提供服务的十家德国诊所关于参与意愿和参与障碍的经验教训。
Vaccine X. 2023 Apr 14;14:100302. doi: 10.1016/j.jvacx.2023.100302. eCollection 2023 Aug.
4
Patient-centered practices for engaging transgender and gender diverse patients in clinical research studies.以患者为中心的实践,让跨性别和性别多样化的患者参与临床研究。
BMC Med Res Methodol. 2021 Oct 1;21(1):202. doi: 10.1186/s12874-021-01328-4.
5
Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews.受试者参与临床试验的障碍与促进因素:综述概述
Contemp Clin Trials Commun. 2021 Aug 3;23:100829. doi: 10.1016/j.conctc.2021.100829. eCollection 2021 Sep.
6
What motivates or demotivates injecting drug users to participate in hypothetical HIV vaccine efficacy trials? A qualitative study from urban Tanzania.是什么促使或阻碍注射吸毒者参与假设性的艾滋病毒疫苗效力试验?来自坦桑尼亚城市的一项定性研究。
East Afr Health Res J. 2020;4(2):128-139. doi: 10.24248/eahrj.v4i2.636. Epub 2020 Nov 26.
7
Understanding Willingness to Participate in HIV Biomedical Research: A Mixed Methods Investigation.理解参与 HIV 生物医学研究的意愿:一项混合方法研究。
AIDS Behav. 2021 Sep;25(9):2699-2711. doi: 10.1007/s10461-021-03257-1. Epub 2021 Jun 15.
8
Exploring the Engagement of Racial and Ethnic Minorities in HIV Treatment and Vaccine Clinical Trials: A Scoping Review of Literature and Implications for Future Research.探索少数族裔参与 HIV 治疗和疫苗临床试验的情况:文献综述及对未来研究的启示。
AIDS Patient Care STDS. 2020 Sep;34(9):399-416. doi: 10.1089/apc.2020.0008.
9
Factors affecting patient participation in clinical trials in Ireland: A narrative review.影响爱尔兰患者参与临床试验的因素:一项叙述性综述。
Contemp Clin Trials Commun. 2016 Mar 2;3:23-31. doi: 10.1016/j.conctc.2016.01.002. eCollection 2016 Aug 15.
10
Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City.纽约市年轻黑人男男性行为者和跨性别女性参与艾滋病毒疫苗及预防研究的障碍与促进因素
PLoS One. 2017 Jul 19;12(7):e0181702. doi: 10.1371/journal.pone.0181702. eCollection 2017.